Table 5.

Outcomes between groups before and after propensity score matching

	All cohort				Propensity score matched cohort
	ASA	No ASA	%difference	p value	ASA	No ASA	% difference	p value
Primary outcome n (%) In-hospital mortality	1000 (30.4)	2929 (16.9)	+ 13.5%	< 0.001	1000 (30.4)	874 (30.3)	+ 0.1%	0.938
Secondary outcomes n (%) DVT PE DVT + PE High-risk inflammatory category HFNC NIMV IMV ICU admission Combined variable	18 (0.5) 57 (1.7) 4 (0.1) 2637 (80.1) 319 (9.7) 221 (6.7) 213 (6.5) 283 (8.6) 1253 (38.1)	105 (0.6) 303 (1.7) 32 (0.2) 13,058 (75.3) 1647 (9.5) 994 (5.7) 1337 (7.7) 1723 (9.9) 4752 (27.4)	− 0.1% 0 − 0.1%  + 4.8%  + 0.2%  + 1% − 1.2% − 1.3%  + 10.7%	0.851 0.851 0.851 < 0.001 0.720 0.028 0.014 0.018 < 0.001	18 (0.5) 57 (1.7) 4 (0.1) 2637 (80.1) 319 (9.7) 221 (6.7) 213 (6.5) 283 (8.6) 1253 (38.1)	22 (0.8) 41 (1.4) 5 (0.2) 2282 (79.1) 262 (9.1) 182 (6.3) 181 (6.3) 238 (8.2) 1096 (38)	− 0.3%  + 0.3% − 0.1%  + 1%  + 0.6%  + 0.4%  + 0.2%  + 0.4%  + 0.1%	0.508 0.508 0.508 0.316 0.411 0.518 0.750 0.622 0.946

ASA Acetylsalicylic acid, HFNC High Flow nasal cannula, NIMV non-invasive mechanical ventilation, IMV invasive mechanical ventilation, ICU intensive care unit, DVT Deep venous thrombosis, PE Pulmonary embolism